These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 33075099)

  • 1. Clinical performance and utility of a comprehensive next-generation sequencing DNA panel for the simultaneous analysis of variants, TMB and MSI for myeloid neoplasms.
    Sahajpal NS; Mondal AK; Ananth S; Njau A; Ahluwalia P; Jones K; Ahluwalia M; Okechukwu N; Savage NM; Kota V; Rojiani AM; Kolhe R
    PLoS One; 2020; 15(10):e0240976. PubMed ID: 33075099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material.
    Steeghs EMP; Kroeze LI; Tops BBJ; van Kempen LC; Ter Elst A; Kastner-van Raaij AWM; Hendriks-Cornelissen SJB; Hermsen MJW; Jansen EAM; Nederlof PM; Schuuring E; Ligtenberg MJL; Eijkelenboom A
    BMC Cancer; 2020 Apr; 20(1):291. PubMed ID: 32264863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic, Prognostic, and Predictive Utility of Recurrent Somatic Mutations in Myeloid Neoplasms.
    Patel U; Luthra R; Medeiros LJ; Patel KP
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S62-S74. PubMed ID: 28760304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design.
    Aguilera-Diaz A; Vazquez I; Ariceta B; Mañú A; Blasco-Iturri Z; Palomino-Echeverría S; Larrayoz MJ; García-Sanz R; Prieto-Conde MI; Del Carmen Chillón M; Alfonso-Pierola A; Prosper F; Fernandez-Mercado M; Calasanz MJ
    PLoS One; 2020; 15(1):e0227986. PubMed ID: 31978184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Validation of Diagnostic Next-Generation Sequencing Panels for Acute Myeloid Leukemia Patients.
    Wagner U; Wong C; Camenisch U; Zimmermann K; Rechsteiner M; Valtcheva N; Theocharides A; Widmer CC; Manz MG; Moch H; Wild PJ; Balabanov S
    J Mol Diagn; 2022 Aug; 24(8):935-954. PubMed ID: 35718092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid Malignancies.
    Thomas M; Sukhai MA; Zhang T; Dolatshahi R; Harbi D; Garg S; Misyura M; Pugh T; Stockley TL; Kamel-Reid S
    Arch Pathol Lab Med; 2017 Jun; 141(6):759-775. PubMed ID: 28557600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Utility of Targeted Next-Generation Sequencing Assay to Detect Copy Number Variants Associated with Myelodysplastic Syndrome in Myeloid Malignancies.
    Jiang L; Pallavajjala A; Huang J; Haley L; Morsberger L; Stinnett V; Hardy M; Park R; Ament C; Finch A; Shane A; Parish R; Nozari A; Long P; Adams E; Smith K; Parimi V; Dougaparsad S; Long L; Gocke CD; Zou YS
    J Mol Diagn; 2021 Apr; 23(4):467-483. PubMed ID: 33577993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analytical validation and performance characteristics of a 48-gene next-generation sequencing panel for detecting potentially actionable genomic alterations in myeloid neoplasms.
    Rosenthal SH; Gerasimova A; Ma C; Li HR; Grupe A; Chong H; Acab A; Smolgovsky A; Owen R; Elzinga C; Chen R; Sugganth D; Freitas T; Graham J; Champion K; Bhattacharya A; Racke F; Lacbawan F
    PLoS One; 2021; 16(4):e0243683. PubMed ID: 33909614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use.
    Bacher U; Shumilov E; Flach J; Porret N; Joncourt R; Wiedemann G; Fiedler M; Novak U; Amstutz U; Pabst T
    Blood Cancer J; 2018 Nov; 8(11):113. PubMed ID: 30420667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Validation of a Myeloid Next-Generation Sequencing Panel for Single-Nucleotide Variants, Insertions/Deletions, and Fusion Genes.
    Izevbaye I; Liang LY; Mather C; El-Hallani S; Maglantay R; Saini L
    J Mol Diagn; 2020 Feb; 22(2):208-219. PubMed ID: 31751678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes.
    Duncavage EJ; Tandon B
    Int J Lab Hematol; 2015 May; 37 Suppl 1():115-21. PubMed ID: 25976969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies.
    Cao J; Chen L; Li H; Chen H; Yao J; Mu S; Liu W; Zhang P; Cheng Y; Liu B; Hu Z; Chen D; Kang H; Hu J; Wang A; Wang W; Yao M; Chrin G; Wang X; Zhao W; Li L; Xu L; Guo W; Jia J; Chen J; Wang K; Li G; Shi W
    Oncologist; 2019 Dec; 24(12):e1294-e1302. PubMed ID: 31409745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation, Implementation, and Clinical Impact of the Oncomine Myeloid Targeted-Amplicon DNA and RNA Ion Semiconductor Sequencing Assay.
    Ferrone CK; Wong H; Semenuk L; Werunga B; Snetsinger B; Zhang X; Zhang G; Lui J; Richard-Carpentier G; Crocker S; Good D; Hay AE; Quest G; Carson N; Feilotter HE; Rauh MJ
    J Mol Diagn; 2021 Oct; 23(10):1292-1305. PubMed ID: 34365012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Utility of Implementing a Frontline NGS-Based DNA and RNA Fusion Panel Test for Patients with Suspected Myeloid Malignancies.
    Bhai P; Hsia CC; Schenkel LC; Hedley BD; Levy MA; Kerkhof J; Santos S; Stuart A; Lin H; Broadbent R; Nan S; Yang P; Xenocostas A; Chin-Yee I; Sadikovic B
    Mol Diagn Ther; 2022 May; 26(3):333-343. PubMed ID: 35381971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted next-generation sequencing using a multigene panel in myeloid neoplasms: Implementation in clinical diagnostics.
    Maes B; Willemse J; Broekmans A; Smets R; Cruys B; Put N; Madoe V; Janssen M; Soepenberg O; Bries G; Vrelust I; Achten R; Van Pelt K; Buvé K; Theunissen K; Peeters V; Froyen G
    Int J Lab Hematol; 2017 Dec; 39(6):604-612. PubMed ID: 28722833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next-generation sequencing-based panel testing for myeloid neoplasms.
    Kuo FC; Dong F
    Curr Hematol Malig Rep; 2015 Jun; 10(2):104-11. PubMed ID: 25933675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analytical Validation of a 37-Gene Next-Generation Sequencing Panel for Myeloid Malignancies and Review of Initial Findings Incorporating Updated 2022 Diagnostic and Prognostic Guidelines.
    Leung B; Aung H; Nandini A; Abdulrasool G; Lau C; Seymour L
    J Mol Diagn; 2024 May; 26(5):399-412. PubMed ID: 38367765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next generation sequencing in therapy-related myeloid neoplasms compared to
    Claerhout H; Vranckx H; Lierman E; Michaux L; Boeckx N
    Acta Clin Belg; 2022 Jun; 77(3):658-663. PubMed ID: 34197279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.
    Vanderwalde A; Spetzler D; Xiao N; Gatalica Z; Marshall J
    Cancer Med; 2018 Mar; 7(3):746-756. PubMed ID: 29436178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategy for identification of a potential inherited leukemia predisposition in a 299 patient's cohort with tumor-only sequencing data.
    Aguilera-Diaz A; Larrayoz MJ; Palomino-Echeverría S; Vazquez I; Ariceta B; Mañú A; Blasco-Iturri Z; Bernal Del Castillo T; Olivares Salaverri M; Olave Rubio MT; Rifon-Roca J; Alfonso-Pierola A; Prosper F; Fernandez-Mercado M; Calasanz MJ
    Leuk Res; 2020 Aug; 95():106386. PubMed ID: 32512379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.